By Ronda Fears
Memphis, Sept. 21 - Home Diagnostics, Inc. raised $39.6 million in proceeds from its initial public offering of 3.3 million shares at $12 each, below price talk of $14 to $16, via bookrunner JPMorgan and joint lead manager Piper Jaffray.
At the same time, there was a secondary offering of 3.3 million shares, with a greenshoe of 990,000 shares available, by selling shareholders at the same price.
Fort Lauderdale, Fla.-based Home Diagnostics develops blood glucose monitoring systems and disposable supplies for diabetics. The company plans to use proceeds to redeem preferred stock, to purchase manufacturing equipment, to repay debt and for general corporate purposes.
| Issuer: | Home Diagnostics, Inc.
|
| Issue: | Initial public offering
|
| Amount: | $39.6 million
|
| Shares: | 3.3 million
|
| Greenshoe: | 450,000 shares
|
| Price: | $12 per share
|
| Price talk: | $14 to $16 per share
|
| Bookrunner: | JPMorgan
|
| Joint lead manager: | Piper Jaffray
|
| Co-managers: | Deutsche Bank Securities and William Blair & Co.
|
| Pricing date: | Sept. 20
|
| Settlement date: | Sept. 25
|
| Stock symbol: | Nasdaq: HDIX
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
